{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:26:40Z","timestamp":1790105200965,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007605","name":"Aarhus University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R381-2021-1405"],"award-info":[{"award-number":["R381-2021-1405"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R313-2019-790"],"award-info":[{"award-number":["R313-2019-790"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"publisher","award":["9060-00023B"],"award-info":[{"award-number":["9060-00023B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Achieving antiretroviral therapy (ART)-free virologic control remains a central goal in human immunodeficiency virus (HIV) cure research. To identify factors associated with time to detectable viremia and time to loss of virologic control, we conducted a pooled analysis of 6 interventional trials that included analytical ART interruption.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We determined factors influencing time to detectable viremia (plasma HIV-RNA \u226550 copies\/mL) and loss of virologic control (2 consecutive measurements of plasma HIV-RNA \u22655000 copies\/mL or restart of ART) using Cox proportional hazard regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 91 included participants we found that high levels of total HIV-DNA (\u2265750 copies\/mL) and intact proviral DNA (\u226580 copies\/106 CD4+ T cells) were both associated with shorter time to detectable viremia (hazard ratio [HR] = 1.98; 95% confidence interval [CI], 1.22\u20133.22 and HR = 1.67; 95% CI, 1.08\u20132.58, respectively). Total HIV-DNA \u2265750 copies\/106 CD4+ T cells also predicted shorter time to loss of virologic control (HR = 1.64; 95% CI, 1.01\u20132.67), as did longer time (\u22651 year) from HIV diagnosis to ART start (HR = 1.56; 95% CI, 1.02\u20132.39). Having received histone deacetylase inhibitors predicted shorter time to loss of virologic control (HR = 2.22; 95% CI, 1.12\u20134.41), while broadly neutralizing anti-HIV-1 antibody treatment at ART initiation of individuals harboring 3BNC117-sensitive viruses trended towards delayed time to loss of virologic control (HR = 0.32; 95% CI, .10\u20131.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings highlight the positive impact of early ART and low HIV reservoirs on time to rebound among people undergoing analytical treatment interruption and provides new insight into therapeutic interventions aimed at achieving virologic control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf163","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:55:46Z","timestamp":1743267346000},"page":"69-78","source":"Crossref","is-referenced-by-count":10,"title":["Factors Influencing Virologic Control During Analytical Treatment Interruptions in HIV Cure Trials\u2014a Pooled Analysis of Individual-Level Data"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-4207","authenticated-orcid":false,"given":"Vibeke","family":"Klastrup","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Infectious Diseases, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-0259","authenticated-orcid":false,"given":"Jesper Damsgaard","family":"Gunst","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Infectious Diseases, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Aagaard","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Infectious Diseases, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Infectious Diseases, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Schmeltz","family":"S\u00f8gaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Infectious Diseases, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025073007430283500_jiaf163-B1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995\u20132005","volume":"146","author":"Lohse","year":"2007","journal-title":"Ann Intern Med"},{"key":"2025073007430283500_jiaf163-B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/592692","article-title":"Hospitalization for pneumonia among individuals with and without HIV infection, 1995\u20132007: a Danish population-based, nationwide cohort study","volume":"10","author":"Sogaard","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025073007430283500_jiaf163-B3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41467-025-56116-1","article-title":"Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies","volume":"16","author":"Gunst","year":"2025","journal-title":"Nat Commun"},{"key":"2025073007430283500_jiaf163-B4","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/01.aids.0000327438.13291.62","article-title":"Stigma in the HIV\/AIDS epidemic: a review of the literature and recommendations for the way forward","volume":"22","author":"Mahajan","year":"2008","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B5","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1097\/QAD.0b013e3283320dce","article-title":"HIV-related stigma and psychological distress: the harmful effects of specific stigma manifestations in various social settings","volume":"23","author":"Stutterheim","year":"2009","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B6","doi-asserted-by":"crossref","first-page":"16356","DOI":"10.1038\/s41598-022-19970-3","article-title":"Elite controllers long-term non progressors present improved survival and slower disease progression","volume":"12","author":"Capa","year":"2022","journal-title":"Sci Rep"},{"key":"2025073007430283500_jiaf163-B7","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study: e1003211","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog"},{"key":"2025073007430283500_jiaf163-B8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-981-13-0484-2_12","article-title":"Clinical interventions in HIV cure research","volume":"1075","author":"Rasmussen","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2025073007430283500_jiaf163-B9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"2025073007430283500_jiaf163-B10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"2025073007430283500_jiaf163-B11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"2025073007430283500_jiaf163-B12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat Med"},{"key":"2025073007430283500_jiaf163-B13","doi-asserted-by":"crossref","first-page":"eabg3071","DOI":"10.1126\/scitranslmed.abg3071","article-title":"The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy","volume":"13","author":"SenGupta","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025073007430283500_jiaf163-B14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fimmu.2020.01112","article-title":"The use of Toll-like receptor agonists in HIV-1 cure strategies","volume":"11","author":"Martinsen","year":"2020","journal-title":"Front Immunol"},{"key":"2025073007430283500_jiaf163-B15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ebiom.2019.07.005","article-title":"TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes","volume":"45","author":"Schleimann","year":"2019","journal-title":"EBioMedicine"},{"key":"2025073007430283500_jiaf163-B16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025073007430283500_jiaf163-B17","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat Med"},{"key":"2025073007430283500_jiaf163-B18","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"2025073007430283500_jiaf163-B19","doi-asserted-by":"crossref","first-page":"101619","DOI":"10.1016\/j.bjid.2021.101619","article-title":"The influence of HLA\/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view","volume":"25","author":"Lunardi","year":"2021","journal-title":"Braz J Infect Dis"},{"key":"2025073007430283500_jiaf163-B20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","article-title":"CD8+ T cells in HIV control, cure and prevention","volume":"20","author":"Collins","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025073007430283500_jiaf163-B21","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","article-title":"Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity","volume":"13","author":"Ros\u00e1s-Umbert","year":"2022","journal-title":"Nat Commun"},{"key":"2025073007430283500_jiaf163-B22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni845","article-title":"HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors","volume":"3","author":"Connors","year":"2002","journal-title":"Nat Immunol"},{"key":"2025073007430283500_jiaf163-B23","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1172\/JCI120549","article-title":"HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers","volume":"128","author":"Sharaf","year":"2018","journal-title":"J Clin Invest"},{"key":"2025073007430283500_jiaf163-B24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11904-021-00569-8","article-title":"Analytical treatment interruption in HIV trials: statistical and study design considerations","volume":"18","author":"Zheng","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025073007430283500_jiaf163-B25","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"2025073007430283500_jiaf163-B26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24-week toll-like receptor 9 agonist treatment in HIV type 1 + individuals","volume":"33","author":"Vibholm","year":"2019","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B27","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025073007430283500_jiaf163-B28","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat Med"},{"key":"2025073007430283500_jiaf163-B29","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/QAD.0000000000000734","article-title":"A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control","volume":"29","author":"Assoumou","year":"2015","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B30","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/infdis\/jiaa270","article-title":"Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy","volume":"222","author":"Sneller","year":"2020","journal-title":"J Infect Dis"},{"key":"2025073007430283500_jiaf163-B31","doi-asserted-by":"crossref","first-page":"648434","DOI":"10.3389\/fmicb.2021.648434","article-title":"Predicting post-treatment HIV remission: does size of the viral reservoir matter?","volume":"12","author":"Pasternak","year":"2021","journal-title":"Front Microbiol"},{"key":"2025073007430283500_jiaf163-B32","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/QAD.0b013e328360a4bd","article-title":"MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection","volume":"27","author":"Antoni","year":"2013","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B33","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1097\/QAD.0b013e32833b61ba","article-title":"Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection","volume":"24","author":"Hocqueloux","year":"2010","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"2025073007430283500_jiaf163-B35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly neutralizing antibodies for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"2025073007430283500_jiaf163-B36","doi-asserted-by":"crossref","first-page":"e1004287","DOI":"10.1371\/journal.ppat.1004287","article-title":"Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes","volume":"10","author":"Jones","year":"2014","journal-title":"PLoS Pathog"},{"key":"2025073007430283500_jiaf163-B37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000002112","article-title":"In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals","volume":"33","author":"Garrido","year":"2019","journal-title":"AIDS"},{"key":"2025073007430283500_jiaf163-B38","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/jmv.21907","article-title":"High HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir","volume":"82","author":"Piketty","year":"2010","journal-title":"J Med Virol"},{"key":"2025073007430283500_jiaf163-B39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijid.2023.01.025","article-title":"Factors associated with post-treatment control of viral load in HIV-infected patients: a systematic review and meta-analysis","volume":"129","author":"Zhou","year":"2023","journal-title":"Int J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf163\/62749135\/jiaf163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/1\/69\/62749135\/jiaf163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/1\/69\/62749135\/jiaf163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:43:16Z","timestamp":1753875796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/1\/69\/8096499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf163","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2025,3,26]]}}}